Six NACT Cycles Before Surgery Fail to Improve DFS in Advanced Ovarian Cancer

Delaying cytoreductive surgery until after 6 cycles of neoadjuvant chemotherapy did not improve DFS vs interval surgery after 3 cycles in patients with advanced high-grade epithelial ovarian cancer.

Six NACT Cycles Before Surgery Fail to Improve DFS in Advanced Ovarian Cancer. Delaying cytoreductive surgery until after 6 cycles of neoadjuvant chemotherapy did not improve DFS vs interval surgery after 3 cycles in patients with advanced high-grade epithelial ovarian cancer. Surgery after 6 cycles of neoadjuvant chemotherapy (NACT) did not improve outcomes nor meet the primary end point of disease-free survival (DFS) compared with surgery after 3 cycles of NACT among patients with advanced high-grade epithelial ovarian cancer, according to results from the phase 2 CHRONO trial (NCT03579394) shared at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. At a median follow-up of 40.4 months (range, 0.03–72.7), median DFS was 23.4 months (95% CI, 19.0–30.4) in the 6-cycle arm vs 20.2 months (95% CI, 18.2–23.6) in the 3-cyc...